Genkyotex provides business update and reports gross cash position at December 31, 2019
(WorldNews France)

COMMUNIQUÉ DE PRESSE Archamps (France), January 16, 2020 at 07:30 pm CET GENKYOTEX PROVIDES BUSINESS UPDATE AND REPORTS GROSS CASH POSITION AT DECEMBER 31, 2019 GROSS CASH AND CASH EQUIVALENTS OF EUR2.4 MILLION AS OF DECEMBER 31, 2019 PHASE 2 IPF NIH-FUNDED TRIAL FIRST PATIENT IN EXPECTED FEBRUARY 2020 PHASE 3 PBC TRIAL DESIGN EXPECTED TO BE AGREED WITH FDA WITHIN THE FIRST HALF OF 2020 NO CONVERTIBLE DEBT OUTSTANDING AS OF JANUARY 15, 2020 Genkyotex (Euronext Paris & Brussels: FR0013399474 - GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today gross cash and cash equivalents of EUR2.4 million as of December 31, 2019. The existing gross cash and cash...